This suggests that NSCLC with ALK fusion is relatively homogenous and may display features of oncogene addiction, which, in turn, may explain higher median survival of patients with ALK fusions treated with ALK-TKIs compared to that of patients with EGFR mutations treated with EGFR-TKIs [8,22]. This evidence concerns the gene ALK and non-small cell lung carcinoma.